Heidi Carias

Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor

Kam Y. J. Zhang, G. Habets, P. Hirth, 2013, Proceedings of the National Academy of Sciences.

BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor.

Lindsey T. Brinton, J. Byrd, G. Habets, 2018, Cancer discovery.

KRAS insertion mutations are oncogenic and exhibit distinct functional properties

M. Loh, K. Shannon, G. Bollag, 2016, Nature Communications.

RAF inhibitors that evade paradoxical MAPK pathway activation

James Tsai, Ying Zhang, Paul S. Lin, 2015, Nature.

Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397.

A. Kasarskis, R. Sebra, A. Bashir, 2015, Cancer discovery.

Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors: A Phase 1b/2a Nonrandomized Clinical Trial.

A. Shields, W. Tap, G. Habets, 2021, JAMA oncology.

Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.

Chao Zhang, G. Bollag, Heidi Carias, 2023, JCI insight.